Respiratory Flashcards

1
Q

what is Elastic recoil

A

tendency for lungs to collapse inwards and chest wall to spring outwards

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is compliance and when is it changed

A

change in lung volume and pressure is inversely proportional to wall stiffness
increased by surfacant
increased means easier to fill (elderly, emphysema)
decreased more difficult (fibrosis, pneumonia, ARDS, oedema)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Pulmonary wedge pressure is the equivalent of?

A

pressure of LA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

A-a gradient

A

normal = age/4 + 4
normal in high altitude or hypoventilation
raised in diffusion limitations (fibrosis), V/Q mismatch (COPD, oedema, PE) or R -> L shunt

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Causes of right shift of O2 dissociation curve

A

CADET looks right
CO2 increased
acidosis
DPG increased
Exercise
Temp increased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is eisenmengers syndrome

A

Left to right shunt becomes right to left due to pulm HTN
Cyanosis, clubbing, hypoxia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cyanide symptoms

A

headaches, SOB, drowsiness, seizure, cherry red skin, red venules in retina , bitter almond breath

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cyanide poisening lab findings

A

normal pa02, elevated lactate (HAGMA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cyanide treatment

A

decontamination
hydroxocobalamin
sodium thiosulfate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Carbon monoxide poisening labs

A

normal Pa02, raised carboxyHb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

CO poisening treatment

A

100% O2
hyperbaric if severe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Methhaemoglobinaemia treatment

A

Methylene blue and Vit C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Most common type of head and neck cancer

A

squamous cell carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Fat emboli etiology and sx

A

long bone fractures and liposuction
hypoxia, neuro (reduced GCS, confusion, seizures) and petechial rash

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Head and neck cancer tx

A

pembro and chemo better
PDL >20% can do pembro only
PDL 1-20% - pembro and chemo (5FU and cisplatin)
PDL 0% - chemo only

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Asthma is example of which hypersensitivity

A

Type 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Usual age of diagnosis of idiopathic pulm fibrosis

A

60s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

HRCT pattern of idiopathic pulm fibrosis

A

UIP (subpleural reticular opacities, honeycombing, traction bronchiectasis)
Peripheral and lower lobe predominance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Treatment for idiopathic pulm fibrosis

A

supportive with oxygen
antifibrotics (pirfenidone or nintedanib) -> reduced PFT decline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Type of hypersensitivity in hypersensitivity pneumonitis

A

T3 and 4 mixed
(thermophilic actinomyces and asperigillous)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Difference between acute vs chronic hypersensitivity pneumonitis

A

acute -> agent triggers IgG Ab -> inflammation and neutrophils
chronic -> CD4 Th1 delayed hypersensitivity TLR 2 and 9 pathways
Th1 and Th17 promote lung inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Hypersensitivity pneumonitis HRCT findings

A

mid-upper zone prodominance of centrilobar ground glass and mosaic attenuation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Sarcoidosis classic grnaulomas made of

A

non-necrotising with tightly packed central area with macrophages, epitheloid cells and multinucleated giant cells with CD4 T cells surrounds by CD4 and 8 T and B cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is lofgren syndrome

A

sarcoidosis
bilateral hilar adenopathy plus erythema nodosum plus periarticular arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

2 common/specific skin conditions to sarcoidosis

A

erythema nodosum
lupus pernio

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Lab findings in sarcoidosis

A

raised ACE levels
hypercalcaemia
BAL raised CD4/8 ratio

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Mesothelioma cell markers

A

calretinin
cytokeratin 5/6 in almost all
(carcinomas are -ve)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Treatment for mesothelioma

A

chemo (cisplatin and pemetrexed)
2nd line vinorelbine
RTx for chest wall pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Distribution of lung involvement asbestosis and berylliosis/silicosis/coal workers

A

asbestos in the roof so affects the base of lung
Beryllium/silica/coal in the ground so affects the upper lobes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What is caplan syndrome

A

RA plus pneumoconioses with intrapleural nodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Most likely cancer with asbestos related lung disease

A

bronchogenic carcinoma
(mesothelioma less likely)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Berylliosis histology findings

A

non-caesating granulomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Berylliosis lab findings

A

raised blood beryllium lymphocyte proliferation test (BeLPT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Berylliosis treatment

A

cessation of exposure
if cough, for reduced FVC/TLC/DLCO <70% then glucocoticoids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Silicosis why increased TB risk

A

disrupt phagolysosomes and impair macrophages

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

ARDS treatment

A

mechanical ventilation - reduced TV and increase PEEP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Obstructive sleep apneoa diagnosed as

A

> 5 apnea/hypopnea events per hour if symptomatic
if asymptomatic >15 events per hour (resp distrubance index >15 per hour)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What testing appropriate in sleep apnea

A

if mild OSA or complicated/other sleep disorders -> formal PSG
if mod/severe OSA -> home testing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Ventilation changes in obesity

A

decreased FRC, lung compliance and TLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Diagnosis of pulmonary arterial HTN

A

mPAP >20, PVR > 2 wood units
PCWP <15 to exclude LHD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Gene which is cause of heritable pulmonary artial HTN

A

BMPR2 gene (normally inhibits vascular smooth muscle proliferation)
- inactiviating mutation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Treatment for vasoreactive PAH

A

CCB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

treatment for non-vasoreactive PAH

A

class 1 sx -> monotherapy PDE5, ERA or riociguat
class 2/3 sx -> dual ERA and NO-cGMP therapy
clas 4 -> protanoid combo (epoproterol preferred)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Left heart disease pulm HTN diagnosis

A

mPAP >20 and PCWP >15

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

imaging for CTEPH

A

V/Q best screening, CTPA can help
DSPA is gold standard for confirming and assessing for surgery eligibility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

CTEPH treatment

A

lifelong anticoagulation
if haemodynamically sig (PVR at rest 2-15 units) -> consider thromboendarterectomy
If surgery not an option, riociguat is first line

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Cause of clubbing

A

Plt and megakaryocytes lodge in digital vasculature -> local release of VEGF
associated with pulm fibrosis, cystic fibrosis, bronchiectasis, congenital heart disease, IBD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Lights criteria for effusions

A

pleural LDH/serum LDH >0.6
pleural protein/serum protein >0.5
pleural LDH > 2/3 ULN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

uncomplicated parapneumonic effusion vs complicated

A

uncomplicated - low glucose, low pH, raised PMNs
complicated - lower glucose, very high LDH, lower pH <7.15, raised PMNs

50
Q

TB effusion findings

A

raised ADA

51
Q

pancreatitis associated pleural effusion findings

A

raised amylase

52
Q

chylothorax findings

A

TGLs > 1.24

53
Q

PTX treatment

A

if <2cm and stable - observe
if >2 cm and stable -> aspirate first
if recurrent -> chest drain
if secondary -> VAT, 2nd line non-surg pleurodesis or prolonged chest drain

54
Q

common bugs for lobar pneumonia

A

s pneumoniae
legionella
klebsiella

55
Q

common bugs for bronchopneumonia

A

s pneumoniae
s aures
H influenzae
klebsiella

56
Q

Where does lung cancer tend to metastasis

A

liver, adrenals, bone, brain

57
Q

What cancers give mets to lung

A

breast, colon, prostate and bladder

58
Q

Small cell treatment for stage 1 and 2/3

A

surgery -> adjuvant cisplatin
if LN involvement in 2/3 -> chemo only

59
Q

extensive stage SCLC

A

carboplatin and etoposide plus maintence durvalumab

60
Q

conditions associated with SCLC

A

neurological paraneoplastic
Endocine (cushings due to secretes ACTH and SIADH)

61
Q

SCLC mutations

A

myc oncogenes

62
Q

Which is most common NSCLC

A

Adenocarcinoma

63
Q

driver mutations of adenocarcinoma

A

EGFR 10-35%
ALK 3-7%
ROS1 1%
KRAS

64
Q

Chemotherapy for NSCLC without mutations

A

cisplatin plus pemetrexed
add pembrolizumab if PDL1>1%, if >50% pembro only

65
Q

Treatment if EGFR mutation

A

Erlotinib

66
Q

What do to if NSCLC EGFR positive progresses on erlotinib

A

check for T790 mutation -> if present give osimertinib

67
Q

treatment if ALK mutation in NSCLC

A

crizotinib or alectinib

68
Q

Treatment if NSCLC ROS1 positive

A

crizotinib

69
Q

Common metabolic issue with squamous cell lung ca

A

high Ca (secretes PTHrP)

70
Q

associated condition with large cell carcinoma lung cancer

A

gynaecomastia (secretes HCG)

71
Q

carcinoid syndrome associated with what vit deficiency

A

B3 -> cause pellagra (inflammed skin, diarrhoea, dementia, mouth sores)

72
Q

Bronchial carcinoid tumour prognosis and associated sx

A

good prognosis
carcinoid syndrome

73
Q

MoA of bosentan

A

endothelin-1 receptor antagonist which decreases pulm vascular resistance
ADR: hepatotoxic

74
Q

MoA of sildenafil

A

Phosphodiesterase 5 inhibitors -> raises cGMP which prolongs vasodilatory effect of NO

75
Q

MoA of iloprost, epoprostenol

A

Prostacyclin analogs, direct vasodilatory effects on pulm vasc and systemic arterial vascular beds
ADRs: flushing, jaw pain

76
Q

MoA salbuatmol and formeterol

A

one is short, one is long acting beta-2 agonists

77
Q

MoA of tiotropium, ipratropium

A

muscarinic antagonists, prevents bronchoconstriction

78
Q

MoA omalizumab

A

binds unbound IgE so cant bind to Fc portion of mast cells

79
Q

throphylline MoA

A

likely a PDE inhibitor -> bronchodilation

80
Q

MoA mepolizumab

A

anti IL5 -> prevents eosinophils differenciation, activation and survival

81
Q

Severity of obstruction grading in PFTs

A

mild >70
mod 60-70%
mod severe 50-60
severe 35-50
very severe <35

82
Q

Main 2 antifibrotics and MoA

A

Pirfenidone - TGFB and reduces fibroblast proliferation
Nintedanib - inhibits multiple tyrosine kinases
Both slow disease progression and improves survival, no sx benefit

83
Q

Pirfenidone ADR

A

nausea
photosensitvity rash

84
Q

Nintedanib ADR

A

diarrhoea
weight loss
possible CVD risk
can increase bleeding risk, avoid on anticoagulation

85
Q

Most comon mutation pathway involved in idiopathic pulm fibrosis

A

mutations involving premature shortening of telomeres

86
Q

Pattern of lung disease in RA

A

UIP

87
Q

Pattern of lung disease in Systemic sclerosis

A

NSIP

88
Q

pattern of lung disease in inflammatory myopathies

A

oragnising pneumonia

89
Q

pattern of lung disease in sjogrens

A

lymphoid interstitual pneumonia

90
Q

Names of smoking related ILDs

A

respiratory bronchiolitis - ILD
desquamative interstitual pneumonia
fulminant langerhans cell histiocytosis

91
Q

mutation seen in 50% IPF

A

MUC5b gain of function

92
Q

Mutation causing amyotrophic dermatomyositis with ILD

A

anti-MDA5

93
Q

imaging findings in lymphangioleiomyomatosis

A

pulmonary cysts and renal angiomyolipomas

94
Q

antibody associated with primary alveolar proteinosis

A

GM-CSF

95
Q

What is sampter’s triad

A

asthma
aspirin intolerance
nasal polyps

96
Q

findings of ABPA

A

very high total IgE >1000

97
Q

Omalizumab target

A

IgE

98
Q

Mepolizumab target

A

IL 5 (main cytokines responsible for differenciation of eosinophils)

99
Q

Benefits and risks of triple therapy in COPD vs double

A

triple have reduced exacerbations and hospitilisation, but increased pneumonia risk

100
Q

Most common cause of bactyerial exacerbations of COPD

A

haemophilis, streptococcus, moraxella

101
Q

3 most common causes of pleural effusion

A

malignancy
HF
infection

102
Q

pH indicated by parapneumonic effusion

A

< 7.2

103
Q

Benefit of inhaled hypertonic saline in bronciectasis?

A

Reduce exacerbations
some QOL improvement

104
Q

Pathophysiology of cystic fibrosis

A

CFTR usually allows Cl to leave the cell, if not able to leave, increase in Na uptake from lungs via ENaC, which brings water with it, drying out secretions

105
Q

Cystic fibrosis mutations

A

DF508
G551D

106
Q

Ivacaftor MoA

A

CFTR potentiator (opens channel of protein)
used in homozygous DF508 mutations

107
Q

Cystic fibrosis criteria for lung transplant referral

A

FEV1 < 35%
increase freq of IV abx
pO2 < 60
pCO2 >50
clinical organism resistance
imapired QOL

108
Q

Pathways for treatment of PAH

A

endothelin
NO
Prostacyclin

109
Q

If evidence of precappillary PAH on RHC, which test would you do and why

A

Vasodilator challenge
- eligible for CCB

110
Q

RHC measurements for PAH

A

mPAP >20

if precapillary PAWP <15
if PAWP >15 suggests left heart failure (no vasodilator therapies)

111
Q

Why are you unable to use vasodilators for group 2 (LV failure) PAH

A

worsening pressure gradient over alveolar bed -> pulm oedema

112
Q

Cardiac sequale post pneumonia

A

new onset HF caused by bacterial translocation into myocardium

113
Q

Normal characteristics of REM sleep

A

atonia on EMG and tonic/phasic eye movements
second half of night

114
Q

definition of apneoa

A

cessation of airflow for > 10 secs

115
Q

Definition of hypopneoa

A

reduction in airflow by 30% or >10 secs followed by 4% O2 desat or EEG arousal

116
Q

apneoa-hypopneoa index severity

A

normal < 5
mild 5-15
mod 15-30
severe >30

117
Q

Benefits of CPAP

A

improves daytime sleepiness, depression, cognitive function, QOL, BP, MVA risk
does not change CVD mortality

118
Q

Leptins role in ventilation and OSA

A

leptin is a respiratory stimulant, if leptin resistance (ie in obesity) then can lead to hypoventilation

119
Q

Difference between Narcolepsy T1 and T2

A

T1: with cataplexy, low Orexin on CSF
T2: without cataplexy, normal orexin
Both have >3mo excessive daytime sleepiness and positive multiple sleep latency tests (<8 mins to sleep)

120
Q

Pathophysiology of narcolepsy

A

Autoimmune destruction of hypothalamic neurons which produce orexin (usually regulate arousal and transition between wake and sleep)

121
Q

What is cataplexy?

A

sudden and transient episode of muscle weakness, asscoiated with concious awareness usually triggered by emotions ie laughing